NCT04367740

Brief Summary

Purpose: To determine the number of asymptomatic individuals who have antibodies to SARS-CoV-2, the virus which causes COVID-19

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
6,313

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 27, 2020

Completed
1 day until next milestone

Study Start

First participant enrolled

April 28, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 29, 2020

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 24, 2022

Completed
4 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2022

Completed
Last Updated

January 9, 2023

Status Verified

January 1, 2022

Enrollment Period

1.8 years

First QC Date

April 27, 2020

Last Update Submit

January 6, 2023

Conditions

Keywords

COVID-19PandemicCOVID-19 virus testing

Outcome Measures

Primary Outcomes (1)

  • Percentage of Asymptomatic patients with an IgG response from SARS-CoV-2 infection.

    Presence or absence of IgG antibodies to SARS-CoV2

    at enrollment

Secondary Outcomes (1)

  • Percentage of Asymptomatic patients with viral presence of SARS-CoV-2 infection.

    at enrollment

Study Arms (1)

Serum Antibodies

Blood samples to be obtained assess for IgG antibodies against SARS-CoV2

Diagnostic Test: To assess for development of IgG antibodies against SARS-CoV2

Interventions

Swabs will be collected to assess for COVID-19 if PPE supplies allow.

Also known as: Nasopharyngeal Swab, Oropharyngeal Swab
Serum Antibodies

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients seen at UNC Outpatient clinics who are asymptomatic for COVID-19 infection

You may qualify if:

  • Individuals aged 18-99 who arrive at any participating UNC Healthcare clinic for care and who have a medical record in UNC EPIC.
  • Patients may be included if they have completed the quarantine as recommended by the CDC and at least 4 weeks since the initial positive COVID-19 NP test.

You may not qualify if:

  • Any individual arriving at any participating UNC Healthcare clinic for diagnosis or treatment of respiratory symptoms meeting the following COVID-19 clinical evaluation criteria:
  • Developed non-allergy respiratory symptoms of cough or shortness of breath in the past 7 days
  • AND
  • Meet ONE OR MORE of these criteria
  • Had close contact (within 6 feet for 10 or more minutes) with a person diagnosed with COVID-19
  • Works in a healthcare setting
  • Is pregnant or postpartum within 2 weeks of delivery
  • Is morbidly obese: BMI = 40 or 100 pounds over ideal body weight
  • Diabetes mellitus
  • Immunosuppression, including caused by medications or by HIV infection
  • Pulmonary disease, including asthma
  • Cardiovascular disease
  • Hypertensive disease
  • Renal disease
  • Hepatic disease
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Center for Environmental Medicine, Asthma and Lung Biology

Chapel Hill, North Carolina, 27599, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood; virus from nasal or oral swab

MeSH Terms

Conditions

Asymptomatic DiseasesVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsRNA Virus InfectionsCommunicable DiseasesCOVID-19

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsInfectionsNidovirales InfectionsPneumonia, ViralPneumoniaRespiratory Tract InfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

  • David B Peden, MD

    University of North Carolina, Chapel Hill

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 27, 2020

First Posted

April 29, 2020

Study Start

April 28, 2020

Primary Completion

February 24, 2022

Study Completion

February 28, 2022

Last Updated

January 9, 2023

Record last verified: 2022-01

Data Sharing

IPD Sharing
Will not share

Locations